Literature DB >> 17555829

Raf kinases: function, regulation and role in human cancer.

Deborah T Leicht1, Vitaly Balan, Alexander Kaplun, Vinita Singh-Gupta, Ludmila Kaplun, Melissa Dobson, Guri Tzivion.   

Abstract

The Ras-Raf-MAPK pathway regulates diverse physiological processes by transmitting signals from membrane based receptors to various nuclear, cytoplasmic and membrane-bound targets, coordinating a large variety of cellular responses. Function of Raf family kinases has been shown to play a role during organism development, cell cycle regulation, cell proliferation and differentiation, cell survival and apoptosis and many other cellular and physiological processes. Aberrations along the Ras-Raf-MAPK pathway play an integral role in various biological processes concerning human health and disease. Overexpression or activation of the pathway components is a common indicator in proliferative diseases such as cancer and contributes to tumor initiation, progression and metastasis. In this review, we focus on the physiological roles of Raf kinases in normal and disease conditions, specifically cancer, and the current thoughts on Raf regulation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17555829      PMCID: PMC1986673          DOI: 10.1016/j.bbamcr.2007.05.001

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  193 in total

1.  Overlapping and specific functions of Braf and Craf-1 proto-oncogenes during mouse embryogenesis.

Authors:  L Wojnowski; L F Stancato; A C Larner; U R Rapp; A Zimmer
Journal:  Mech Dev       Date:  2000-03-01       Impact factor: 1.882

2.  Identification of the mechanisms regulating the differential activation of the mapk cascade by epidermal growth factor and nerve growth factor in PC12 cells.

Authors:  S Kao ; R K Jaiswal; W Kolch; G E Landreth
Journal:  J Biol Chem       Date:  2001-03-13       Impact factor: 5.157

3.  Requirement of Ras-GTP-Raf complexes for activation of Raf-1 by protein kinase C.

Authors:  R Marais; Y Light; C Mason; H Paterson; M F Olson; C J Marshall
Journal:  Science       Date:  1998-04-03       Impact factor: 47.728

4.  Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas.

Authors:  Karin Fransén; Maria Klintenäs; Anna Osterström; Jan Dimberg; Hans-Jürg Monstein; Peter Söderkvist
Journal:  Carcinogenesis       Date:  2003-12-19       Impact factor: 4.944

5.  H-ras and raf-1 cooperate in transformation of NIH3T3 fibroblasts.

Authors:  A Cuadrado; J T Bruder; M A Heidaran; H App; U R Rapp; S A Aaronson
Journal:  Oncogene       Date:  1993-09       Impact factor: 9.867

Review 6.  Raf proteins and cancer: B-Raf is identified as a mutational target.

Authors:  Kathryn E Mercer; Catrin A Pritchard
Journal:  Biochim Biophys Acta       Date:  2003-06-05

7.  The MEK kinase activity of the catalytic domain of RAF-1 is regulated independently of Ras binding in T cells.

Authors:  C E Whitehurst; H Owaki; J T Bruder; U R Rapp; T D Geppert
Journal:  J Biol Chem       Date:  1995-03-10       Impact factor: 5.157

8.  Structure and biological activity of v-raf, a unique oncogene transduced by a retrovirus.

Authors:  U R Rapp; M D Goldsborough; G E Mark; T I Bonner; J Groffen; F H Reynolds; J R Stephenson
Journal:  Proc Natl Acad Sci U S A       Date:  1983-07       Impact factor: 11.205

9.  BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.

Authors:  Scott M Wilhelm; Christopher Carter; Liya Tang; Dean Wilkie; Angela McNabola; Hong Rong; Charles Chen; Xiaomei Zhang; Patrick Vincent; Mark McHugh; Yichen Cao; Jaleel Shujath; Susan Gawlak; Deepa Eveleigh; Bruce Rowley; Li Liu; Lila Adnane; Mark Lynch; Daniel Auclair; Ian Taylor; Rich Gedrich; Andrei Voznesensky; Bernd Riedl; Leonard E Post; Gideon Bollag; Pamela A Trail
Journal:  Cancer Res       Date:  2004-10-01       Impact factor: 13.312

10.  Raf-1 activation disrupts its binding to keratins during cell stress.

Authors:  Nam-On Ku; Haian Fu; M Bishr Omary
Journal:  J Cell Biol       Date:  2004-08-16       Impact factor: 10.539

View more
  95 in total

Review 1.  Human pyruvate kinase M2: a multifunctional protein.

Authors:  Vibhor Gupta; Rameshwar N K Bamezai
Journal:  Protein Sci       Date:  2010-11       Impact factor: 6.725

2.  Noonan syndrome: clinical aspects and molecular pathogenesis.

Authors:  M Tartaglia; G Zampino; B D Gelb
Journal:  Mol Syndromol       Date:  2010-01-15

Review 3.  Pro-oncogenic and anti-oncogenic pathways: opportunities and challenges of cancer therapy.

Authors:  Jiao Zhang; Yan-Hua Chen; Qun Lu
Journal:  Future Oncol       Date:  2010-04       Impact factor: 3.404

Review 4.  Selective Raf inhibition in cancer therapy.

Authors:  Vladimir Khazak; Igor Astsaturov; Ilya G Serebriiskii; Erica A Golemis
Journal:  Expert Opin Ther Targets       Date:  2007-12       Impact factor: 6.902

Review 5.  Targeting signal transduction pathways to eliminate chemotherapeutic drug resistance and cancer stem cells.

Authors:  James A McCubrey; Stephen L Abrams; Kristin Stadelman; William H Chappell; Michelle Lahair; Richard A Ferland; Linda S Steelman
Journal:  Adv Enzyme Regul       Date:  2009-11-04

6.  MiR-7-5p is frequently downregulated in glioblastoma microvasculature and inhibits vascular endothelial cell proliferation by targeting RAF1.

Authors:  Zhiguo Liu; Yuguang Liu; Lianling Li; Zhenkuan Xu; Baibin Bi; Yunyan Wang; Jian Yi Li
Journal:  Tumour Biol       Date:  2014-07-16

Review 7.  Phospholipase D: enzymology, functionality, and chemical modulation.

Authors:  Paige E Selvy; Robert R Lavieri; Craig W Lindsley; H Alex Brown
Journal:  Chem Rev       Date:  2011-09-22       Impact factor: 60.622

8.  Overcoming Resistance to Targeted Anticancer Therapies through Small-Molecule-Mediated MEK Degradation.

Authors:  Jessie Peh; Matthew W Boudreau; Hannah M Smith; Paul J Hergenrother
Journal:  Cell Chem Biol       Date:  2018-06-14       Impact factor: 8.116

Review 9.  From basic research to clinical development of MEK1/2 inhibitors for cancer therapy.

Authors:  Christophe Frémin; Sylvain Meloche
Journal:  J Hematol Oncol       Date:  2010-02-11       Impact factor: 17.388

10.  A genetic screen for anchorage-independent proliferation in mammalian cells identifies a membrane-bound neuregulin.

Authors:  Davide Danovi; Catherine A Cremona; Gisela Machado-da-Silva; Sreya Basu; Luke A Noon; Simona Parrinello; Alison C Lloyd
Journal:  PLoS One       Date:  2010-07-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.